Jubilant Pharmova has announced the appointment of Mr. Ashish Mukkirwar as the new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company, effective from May 23, 2026. This decision was made during the Board of Directors meeting held on May 22, 2026, following the recommendations of the Nomination, Remuneration and Compensation Committee and the Audit Committee.
Mr. Mukkirwar brings over two decades of experience in corporate finance, business finance, capital markets, investor relations, mergers and acquisitions, and strategy. Prior to joining Jubilant Pharmova, he served as Group Vice President & CFO – Global Formulations Business at Glenmark Pharmaceuticals. He also held the position of Group Vice President – Strategy, M&A, and Investor Relations at Glenmark for four years. His previous roles include senior positions at Moelis & Company and UBS Investment Banking, where he gained significant exposure to global capital markets and advisory.
Mr. Mukkirwar holds an MBA from the Indian Institute of Management, Kolkata, and is recognised for his ability to drive financial performance, enable strategic growth, and create long-term stakeholder value.
The appointment follows the resignation of Mr. Arun Kumar Sharma, who stepped down from his role as CFO effective at the close of business hours on May 22, 2026. Mr. Sharma will transition to a new role as an Advisor to the Chairmen. The Board expressed appreciation for Mr. Sharma’s valuable contributions and services during his tenure with the company.
The meeting where these decisions were made commenced at 11:30 A.M. and concluded at 02:10 P.M. The company has assured that the details of these changes will be available on its official website.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).